You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: December 1, 2023


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Avelox

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082173 ↗ Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis Completed Johns Hopkins University Phase 2 2004-10-01 Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.
NCT00158093 ↗ A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo Completed Mylan Bertek Pharmaceuticals Phase 1 2003-06-01 Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7.
NCT00280514 ↗ Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed Medical University of Vienna Phase 4 2006-01-01 Penetration of cefpirome and moxifloaxacin into abscess fluid of humans will be tested. Patients with an abscess scheduled for drainage will receive study drugs (single or multiple dose), pus samples and plasma samples will be collected and analyzed by High pressure liquid chromatography (HPLC). Pharmacokinetics of the study drugs in pus and plasma will be determined using a pharmacokinetic model.
NCT00492024 ↗ BAY12-8039: 5 Days for Sinusitis vs Placebo Completed Bayer Phase 3 2005-01-01 The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, therefore in this study Avelox is considered an investigational drug. In this study Avelox will be compared to placebo.
NCT00537563 ↗ AMS VS MOXI Ketek vs Avelox in AMS Completed Sanofi Phase 3 2002-12-01 Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
NCT00665327 ↗ Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia Completed Bayer Phase 4 2002-11-01 This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged ≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.
NCT00668304 ↗ Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox Completed Bayer Phase 4 2004-06-01 This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Avelox

Condition Name

Condition Name for Avelox
Intervention Trials
Healthy 12
Healthy Volunteers 4
Healthy Subjects 3
Chronic Obstructive Pulmonary Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Avelox
Intervention Trials
Pneumonia 11
Tuberculosis 8
Pneumonia, Bacterial 8
Tuberculosis, Pulmonary 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Avelox

Trials by Country

Trials by Country for Avelox
Location Trials
United States 199
South Africa 45
Peru 21
Argentina 19
Romania 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Avelox
Location Trials
Texas 15
California 10
Ohio 9
Florida 9
Montana 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Avelox

Clinical Trial Phase

Clinical Trial Phase for Avelox
Clinical Trial Phase Trials
Phase 4 10
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Avelox
Clinical Trial Phase Trials
Completed 71
Recruiting 3
Active, not recruiting 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Avelox

Sponsor Name

Sponsor Name for Avelox
Sponsor Trials
AstraZeneca 11
Bayer 10
GlaxoSmithKline 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Avelox
Sponsor Trials
Industry 86
Other 82
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.